| Patented Medicine Prices Review Board Canada | news releases
The Patented Medicine Prices Review Board (PMPRB) released today the third and final part in the Alignment Among Public Formularies in Canada series, which explores the current gaps and overlaps in Canadian public drug plan formularies
| Patented Medicine Prices Review Board Canada | news releases
Patented Medicine Prices Review Board seeks applicants for Chairperson position
| Patented Medicine Prices Review Board Canada | news releases
High-cost drugs accounted for over one third of total drug costs in 2019-20 but were only used by 2% of beneficiaries.
| Patented Medicine Prices Review Board Canada | news releases
The Patented Medicine Prices Review Board published the second in a three part report series on Alignment Among Public Formularies in Canada
| Patented Medicine Prices Review Board Canada | news releases
Federal Minister of Health tables the 2019 Annual Report of the Patented Medicine Prices Review Board
| Patented Medicine Prices Review Board Canada | news releases
Canada still among top 10 OECD countries in terms of access to new drugs
| Patented Medicine Prices Review Board Canada | news releases
The latest edition of the Patented Medicine Prices Review Board (PMPRB) Meds Pipeline Monitor reports that oncology continued to dominate the therapeutic mix of the drug pipeline in 2020.
| Patented Medicine Prices Review Board Canada | news releases
Annual expenditures on drugs in public plans exceeded $12 billion in 2018-19
| Patented Medicine Prices Review Board Canada | news releases
Today, the PMPRB, under the National Prescription Drug Utilization Information System (NPDUIS) initiative, released a chartbook on the market for oncology medicines in Canada.
| Patented Medicine Prices Review Board Canada | news releases
PMPRB completes five year consultative process to strengthen and modernize its regime with release of new Guidelines
